These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27285431)

  • 1. Forced degradation studies: current trends and future perspectives for protein-based therapeutics.
    Chan CP
    Expert Rev Proteomics; 2016 Jul; 13(7):651-8. PubMed ID: 27285431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Industry Perspective on the use of Forced Degradation Studies to Assess Comparability of Biopharmaceuticals.
    Campbell JM; Colombo S; Doyle JL; Filoti DI; Hübner G; Magnenat L; Nowinski AK; Pavon JA; Singh SM; Vo LR; Woods JM; Stokes ESE
    J Pharm Sci; 2024 Mar; 113(3):505-512. PubMed ID: 38103689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forced degradation of therapeutic proteins.
    Hawe A; Wiggenhorn M; van de Weert M; Garbe JH; Mahler HC; Jiskoot W
    J Pharm Sci; 2012 Mar; 101(3):895-913. PubMed ID: 22083792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forced degradation of recombinant monoclonal antibodies: A practical guide.
    Nowak C; K Cheung J; M Dellatore S; Katiyar A; Bhat R; Sun J; Ponniah G; Neill A; Mason B; Beck A; Liu H
    MAbs; 2017; 9(8):1217-1230. PubMed ID: 28853987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.
    Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE
    J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current perspectives on stability of protein drug products during formulation, fill and finish operations.
    Rathore N; Rajan RS
    Biotechnol Prog; 2008; 24(3):504-14. PubMed ID: 18484778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Srai JS; Badman C; Krumme M; Futran M; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
    Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
    J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous flow technology vs. the batch-by-batch approach to produce pharmaceutical compounds.
    Cole KP; Johnson MD
    Expert Rev Clin Pharmacol; 2018 Jan; 11(1):5-13. PubMed ID: 29206489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forced degradation studies of biopharmaceuticals: Selection of stress conditions.
    Tamizi E; Jouyban A
    Eur J Pharm Biopharm; 2016 Jan; 98():26-46. PubMed ID: 26542454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopharmaceutical proteins: opportunities and challenges.
    Birch JR; Onakunle Y
    Methods Mol Biol; 2005; 308():1-16. PubMed ID: 16082021
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial: biopharmaceutical technologies.
    Jungbauer A
    Biotechnol J; 2007 Jun; 2(6):647. PubMed ID: 17570696
    [No Abstract]   [Full Text] [Related]  

  • 16. Lifecycle management for recombinant protein production using mammalian cell culture technology.
    Moran E; Gammell P
    Adv Biochem Eng Biotechnol; 2014; 139():245-56. PubMed ID: 24196316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current trends in the clinical development of peptide therapeutics.
    Saladin PM; Zhang BD; Reichert JM
    IDrugs; 2009 Dec; 12(12):779-84. PubMed ID: 19943221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Size-based Degradation of Therapeutic Proteins - Mechanisms, Modelling and Control.
    Bansal R; Jha SK; Jha NK
    Biomol Concepts; 2021 Jun; 12(1):68-84. PubMed ID: 34146465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Antibody Protein Therapeutics Development & Production--IBC Conference. Successful strategies for bringing protein therapeutics to market.
    Thorne B
    IDrugs; 2009 May; 12(5):271-4. PubMed ID: 19431086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.